Related by context. All words. (Click for frequent words.) 69 mGluR2 NAM 68 selective modulator 68 PDE4 inhibitor 68 Symadex 68 glucocorticoid receptor 68 PSN# [002] 68 alagebrium 67 gamma secretase inhibitor 67 vivo potency 67 selective inhibition 67 teplizumab 67 #ME# 67 alpha#beta# integrin 67 DCCR 67 huN# DM1 67 Tasimelteon 67 receptor inhibitor 67 HuLuc# 67 oral prodrug 67 mGlu2 3 67 PSMA ADC 66 cMET 66 VMAT2 66 R#/MEM 66 ATL# [001] 66 MEK inhibitor 66 liposomal formulation 66 Apoptone 66 orally bioavailable 66 Spiegelmer ® 66 histone deacetylase inhibitor 66 IAP inhibitor 66 TKM ApoB 66 neuroprotective properties 66 5 HT2C receptor 66 pharmacodynamic PD 66 CDK inhibitor 66 JAK inhibitor 66 partial agonist 66 PPARγ 66 IL #E 66 Lenocta 66 nicotinic alpha 7 66 MGd 66 vidofludimus 65 davunetide intranasal AL 65 Preclinical studies suggest 65 AEG# 65 receptor partial agonist 65 JAK3 65 ARIKACE ™ 65 R#/MEM # 65 VEGF receptor 65 prostanoid 65 glucagon receptor 65 insulin sensitizing 65 mertansine 65 investigational humanized monoclonal antibody 65 urocortin 2 65 favorable pharmacokinetic profile 65 ENMD # 65 selective androgen receptor modulator 65 TRX1 65 #beta HSD1 65 Phenserine 65 PEG SN# 65 TRIOLEX 65 anti CD3 65 hypoxia inducible factor 65 FGFR 65 pharmacological chaperone 65 orally administered inhibitor 65 Clusterin 64 JAK inhibitors 64 chemokine receptor 64 pathophysiological effects 64 Mipomersen 64 preclinically 64 STAT3 signaling 64 CCR1 64 aurora kinase 64 JAK1 64 uricase 64 PDGF receptor 64 peroxisome proliferator activated 64 Xanafide 64 TH# [003] 64 SPC# [001] 64 CORT # 64 Azedra 64 CD# CEA 64 effector function 64 Archexin 64 elotuzumab 64 Granulocyte Colony Stimulating Factor 64 miglustat 64 PCK# 64 Sapacitabine 64 HIF PH inhibitors 64 XmAb# 64 ISIS # 64 INCB# [001] 64 alvespimycin 64 NOX E# 64 CCX# 64 mitogen activated protein kinase 64 metaglidasen 64 TNF receptors 64 Phase 1a clinical 64 OXi# 64 DXL# 64 fosbretabulin 64 P#X# 64 NMDA antagonist 64 E#F# 64 anti fibrotic 64 SAR# [002] 64 systemically administered 64 ERK1 2 64 Androxal TM 64 nucleotide analog 64 eniluracil 63 orally dosed 63 transgenic mouse models 63 Triolex 63 Onconase 63 novel VDA molecule 63 TRAIL induced apoptosis 63 Aurora kinase 63 lomitapide 63 HQK 63 non nucleoside 63 Bezielle 63 preclinical efficacy 63 sodium glucose cotransporter 63 cyclin dependent kinase inhibitor 63 Squalamine 63 PKC# 63 potently inhibit 63 incretin 63 SGS# 63 SIRT2 63 immunomodulatory 63 pharmacodynamic markers 63 Eniluracil 63 PD LID 63 PS# [001] 63 parathyroid hormone PTH 63 Ataluren 63 receptor blocker 63 EndoTAG TM -1 63 ASONEP 63 agonists antagonists 63 synthetic retinoid 63 Prodarsan ® 63 antiapoptotic 63 CEQ# 63 HGS ETR2 63 JVRS 63 Lixivaptan 63 ELND# 63 selective antagonist 63 Dasatinib 63 beta 1a 63 polymerase inhibitor 63 N acetylgalactosamine 6 63 MAXY VII 63 mediated inhibition 63 acetylcholinesterase 63 TLR9 63 AKT inhibitor 63 Poly ICLC 63 anti amnesic 63 flavopiridol 63 small molecule activators 63 tiapamil 63 CBLC# 63 CD# ligand 63 cilengitide 63 soluble tumor necrosis 63 riociguat 63 Sym# 63 antiangiogenic 63 fibrotic disease 63 PRTX 63 HIF 1alpha 63 nonclinical studies 63 muscarinic 63 neuronal dysfunction 63 antitumoral 63 Cytochrome P# 63 antidepressant efficacy 63 romazarit 63 Fibroblast Growth Factor Receptor 63 ADAMTS# 63 glycogen synthase kinase 63 generation purine nucleoside 63 vascular disrupting agent 63 schizophrenia CIAS 63 γ secretase 63 HIF 1a 63 5 HT2C 63 androgen receptor AR 63 trodusquemine 63 Maxy G# 63 HSP# inhibitor 63 Dapagliflozin 63 CTAP# Capsules 63 pharmacodynamic properties 63 p# mitogen activated 63 Lisofylline LSF 63 RhuDex R 62 JAK2 enzyme 62 hyperphenylalaninemia HPA due 62 PNP inhibitor 62 CCR9 62 Factor VIIa 62 APOPTONE 62 Lu AA# 62 TLR7 62 thrombin receptor 62 LY# [002] 62 SERMs 62 pharmacodynamic effects 62 SGLT2 62 JAK2 inhibitor 62 PDE7 inhibitors 62 AAG geldanamycin analog 62 small molecule activator 62 mTOR mammalian target 62 TLR3 62 rhMBL 62 protein kinase C 62 neurotrophic factor 62 Plicera 62 HCV protease 62 pharmacokinetic PK profile 62 Hypoxia Inducible Factor 62 LY# [003] 62 CYT# potent vascular disrupting 62 5 HT6 receptor 62 receptor tyrosine kinase inhibitor 62 Panzem R 62 CD4 monoclonal antibody 62 antisense drug 62 antitumor effects 62 nucleoside analog 62 immune modulator 62 epothilone 62 antiproliferative activity 62 Pimavanserin 62 P2X 62 Traficet EN 62 Personalized Immunotherapy 62 Blinatumomab 62 GHRH 62 Aviptadil 62 radiolabeled 62 rhIGFBP 3 62 clusterin 62 targeting CD# 62 IFN α 62 Fc fusion protein 62 GPR# [002] 62 thymalfasin 62 rBChE 62 TrkB 62 Guanilib 62 insulin sensitizers 62 tumorigenicity 62 ERK signaling 62 ataluren 62 AQ4N 62 K RAS 62 neuronal differentiation 62 glucose homeostasis 62 bardoxolone 62 MAPK pathway 62 PLK1 SNALP 62 secretory phospholipase A2 sPLA2 62 JAK2 Inhibitor 62 pharmacodynamic profile 62 Enzastaurin 62 mda 7 62 endogenous ligands 62 natriuretic peptide 62 endothelial nitric oxide synthase 62 interferon lambda 62 generation antisense inhibitor 62 UCP2 62 histone deacetylase 62 Vidofludimus 62 Presents Preclinical 62 PDE4 62 sGC 62 BXT # 62 IFN γ 62 selective agonist 62 Protein Kinase C 62 Prestara 62 mGluR4 62 Corgentin 62 induce apoptosis 62 atacicept 62 CD# monoclonal antibody 62 ATL/TV# 62 davunetide 62 tyrosine phosphorylation 62 Trandolapril 62 non nucleoside inhibitor 62 inverse agonist 62 GAMMAGARD 62 PDGFR 62 mitogen activated protein 62 cannabinor 62 small molecule agonists 62 Aurora Kinase 62 polyamine 62 FLT3 62 T#I [002] 62 5 HT1A receptor 62 HuMax EGFr 62 mitogenic 62 ZFP TF 62 subtype selective 62 Zoraxel 62 cardiac contractility 62 JAK2 62 interleukin IL -# 62 enzastaurin 62 Anavex #-# 62 FKBP# 62 neuro protective 62 cytoprotective 62 Cloretazine 62 ON #.Na 62 CCR5 mAb 62 PEGylated interferon 62 RNA antagonist 62 ALN TTR 62 Phase Ib clinical 62 IMC #B 62 Kinase Inhibitor 62 selective inhibitors 62 Ecallantide 62 Huntexil 62 ANAVEX #-# [003] 62 demonstrated antitumor activity 62 tarenflurbil 62 Aß 62 anticancer agent 62 receptor agonist 62 MTP inhibitor 62 therapeutic monoclonal antibody 62 mGluR5 NAM 62 neurotrophic 62 MDV# 62 thymidylate synthase TS 62 Virulizin ® 62 mecamylamine 62 topoisomerase II inhibitor 61 immune stimulatory 61 miR #a [001] 61 FGFR4 61 selectively inhibit 61 Bendavia 61 Curaxin CBLC# 61 selective kinase inhibitor 61 Bicifadine 61 immune modulating 61 neuroprotective effects 61 Rasagiline 61 leukotriene B4 61 somatostatin 61 triphendiol 61 otelixizumab 61 PI3K/mTOR 61 hippocampal neurogenesis 61 LRAT 61 pharmacokinetics pharmacodynamics 61 FGFR2 61 ThGRF 61 Lubiprostone 61 IL 1ß 61 uroguanylin 61 poly ADP ribose polymerase 61 Azacitidine 61 Gleevec resistant 61 PPARgamma 61 TACI Ig 61 PHX# 61 ApoB SNALP 61 #HT#A 61 Trofex 61 Aldosterone 61 Linagliptin 61 PhG alpha 1 61 Omacetaxine mepesuccinate 61 metreleptin 61 A3 adenosine receptor 61 immunotoxin 61 Receptor Antagonist 61 Safinamide 61 CB2 receptor 61 highly selective inhibitor 61 interferon IFN 61 SRT# [003] 61 antidiabetic 61 ALK inhibitor 61 Eg5 61 Meets Primary Endpoint 61 mTOR inhibition 61 dexpramipexole 61 vWF 61 trial evaluating PRX# 61 entinostat 61 volociximab 61 AEGR 61 erythropoietic 61 peptidomimetic 61 GLYX 61 PPARg 61 β amyloid 61 ALN TTR# 61 SNT MC# 61 CCR9 antagonist 61 Janus kinase 61 SCD1 61 histone deacetylases 61 cytostatic 61 rHuPH# 61 ENaC 61 gefitinib Iressa 61 SomatoKine 61 Rigel R# 61 Solorel TM 61 NS#/#A protease 61 partial agonists 61 HCV replication 61 immunomodulation 61 castrate resistant prostate cancer 61 PRT# 61 Preclinical studies 61 Bortezomib 61 PF # [001] 61 elastase 61 PTP 1B 61 reversible inhibitor 61 VEGFR2 61 UGT#A# 61 novel histone deacetylase 61 IAP inhibitors 61 transgenic mouse model 61 cytokines IL 61 cis retinoic acid 61 miR #a [002] 61 Phase 2a clinical trials 61 phase IIb clinical 61 TBC# 61 mineralocorticoid receptor 61 omecamtiv mecarbil 61 antisense inhibitor 61 immunostimulatory effects 61 ONCONASE R 61 HCV protease inhibitors 61 pan HDAC inhibitor 61 Phase Ib study 61 inhibitory activity 61 lysophosphatidic acid 61 Multiple Ascending Dose 61 angiogenesis inhibitor 61 paricalcitol 61 PXD# 61 replicon 61 FOLOTYN ® 61 HDAC Inhibitor 61 eIF4E 61 KSP inhibitors 61 vascular disrupting agents 61 CCR3 61 CG# [003] 61 alpha 2A 61 Hsp# Inhibitor 61 Cdc7 61 glycosylated 61 mTOR inhibitor 61 Akt activation 61 OMP #M# 61 Janus Kinase 61 SYN# 61 Tyrima 61 novel prodrug 61 5 HT2A serotonin 61 Smac mimetics 61 receptor activation 61 SCH # 61 gemcitabine Gemzar ® 61 c MET 61 PKC inhibitor 61 optimal dosing regimens 61 Systemic Delivery 61 S#P# 61 Teriflunomide 61 teduglutide 61 RAR beta 61 activin 61 thyrotropin 61 IL 1beta 61 interferon gamma 1b 61 TLK# 61 plasma kallikrein 61 humanized monoclonal 61 CCR2 61 tolerability pharmacokinetics 61 Nalmefene 61 ELACYT 61 lysophosphatidic acid LPA 61 Annamycin 61 inhibit metastasis 61 KRN# 61 apoptosis proteins 61 Caprospinol 61 K ras mutations 61 methyl D aspartate 61 IMiDs ® 61 sitaxsentan 61 MORAb 61 BRAF kinase 61 cleavable linker 61 targeted radiotherapeutic 61 alefacept 61 gastrin 61 chemopreventive agent 61 tramiprosate 61 PDE# inhibitors 61 Reverse Cholesterol Transport 61 Androgen Receptor 61 promoter methylation 61 HDACi 61 induces apoptosis 61 CYP#D# 61 MetAP2 61 preclinical pharmacokinetic 61 Panzem 61 inducible nitric oxide synthase 61 Factor Receptor 61 HSP# inhibitors 61 N methyl 61 ZOLINZA 61 2A receptor agonist 61 cholesteryl ester transfer 61 glucocorticoid 61 GSK3B 61 immunostimulatory 61 exon skipping 60 antiproliferative effects 60 humanized anti 60 reslizumab 60 T1DM 60 decitabine 60 diabetic neuropathic pain 60 murine model 60 antibody MT# 60 Phase IIa trials 60 Epidermal Growth Factor Receptor 60 Anticalins ® 60 bFGF 60 T2DM 60 siRNA therapeutic 60 selective GR 60 gonadotrophin releasing hormone GnRH 60 PDE1 60 receptor subtypes 60 corticosteroid dexamethasone 60 Phase Ib clinical trials 60 gamma secretase 60 adenosine A2A 60 CCR5 antagonist 60 Protexia ® 60 siRNA therapeutics 60 Genasense ® oblimersen 60 immunoregulatory 60 AERx iDMS 60 pharmacokinetic profile 60 CYP# [002] 60 EZN 60 rivastigmine Exelon 60 midstage trials 60 viral kinetics 60 HepG2 cells 60 NPC 1C 60 selective inhibitor 60 MCSP respectively 60 INS# [001] 60 Treg cell 60 varespladib 60 p# biomarker 60 gonadotropin releasing hormone GnRH 60 transient receptor 60 Hsp# inhibition 60 neuroprotectant 60 Pharmacokinetic studies 60 investigational atypical antipsychotic 60 Protexia R 60 CTA# 60 hENT1 60 synthetic siRNA 60 Phase #b/#a trial 60 triglyceride lowering 60 adecatumumab MT# 60 genomic biomarker 60 TMEM#B 60 amylin 60 rxRNA 60 Phase IIB 60 epigenetic therapies 60 leukemia AML 60 potent anti angiogenic 60 immunomodulatory effects 60 hydroxylase 60 Degarelix 60 MAGE A3 ASCI 60 Maribavir 60 IgG1 antibody 60 plasma pharmacokinetics 60 peptide conjugated 60 ACh 60 TRAIL receptor 60 rhIL 7 60 CatB 60 PEGylated 60 isoform selective 60 AVE# 60 antitumor efficacy 60 cortisol synthesis 60 biodistribution 60 Fulvestrant 60 PEG Interferon lambda 60 FGF2 60 ATL# [002] 60 alkylating agent 60 oxysterols 60 GSTP1 60 Seliciclib 60 tasimelteon 60 sorafenib tablets 60 RNA antagonists 60 Receptor Antagonists 60 effector functions 60 Fas ligand 60 AMD# [003] 60 antisense oligonucleotide 60 reductase 60 anti CD3 antibody 60 tumor antigen 60 HuMax CD# 60 Protease Inhibitor 60 carcinoembryonic antigen 60 selectively inhibits 60 multicenter Phase II 60 cholesterol homeostasis 60 XOMA 3AB 60 CYC# 60 Cetrorelix 60 oral ghrelin agonist 60 IL# PE#QQR 60 PEGylated Fab fragment 60 HDAC inhibition 60 AT1R 60 GRNCM1 60 histone acetylation 60 HDAC inhibitors 60 tipifarnib 60 MEK ERK 60 NNRs 60 interferon γ 60 Receptor Agonist 60 PI3K inhibitor 60 peptide antigens 60 plasmid encoding 60 phosphate S1P 60 ghrelin receptor 60 Glucagon Like Peptide 60 GLPG# 60 HGS# 60 5 HT2A receptor 60 TÎ ² 4 60 ABCB1 60 chemokine SDF 1 60 intranasal formulation 60 Cethromycin 60 VA# [002] 60 Solulin 60 p# activation 60 leukotriene pathway 60 2 inhibitor CYT# 60 lumiliximab 60 multi kinase inhibitor 60 Initiate Phase 60 thetreatment 60 alpha#beta# 60 virus HCV protease inhibitor 60 small molecule thrombopoietin 60 MAXY G# 60 dose dependently 60 ß amyloid 60 PDE inhibitor 60 HbF 60 potent inhibitor 60 ACAPODENE 60 Interferon alpha 60 anticancer activity 60 safinamide 60 ibudilast 60 GPx 60 vesicular monoamine transporter 60 Factor IX 60 ErbB3 60 EGFR signaling 60 immunotherapeutic vaccine 60 THR beta agonist 60 Phase IIIb clinical 60 immunomodulating 60 A2A receptor 60 Upregulation 60 Presents Preclinical Data 60 serine protease 60 thalidomide Thalomid 60 5alpha reductase 60 microglial activation 60 MEK inhibitor RDEA# 60 PLA2 60 potentiator 60 immune modulatory 60 GFT# 60 Familial Adenomatous Polyposis FAP 60 phase IIb trial 60 Arimoclomol 60 Decitabine 60 siRNAs targeting 60 IGF 1R inhibitor 60 Darapladib 60 monocytes macrophages 60 hyaluronidase enzyme 60 nicotinic receptor 60 Phase IIb trials 60 GSK# [002] 60 DNA methyltransferases 60 ganaxolone 60 renal fibrosis 60 CXB# 60 humanised antibody 60 kinase inhibition 60 eIF 4E 60 vorinostat 60 biologic therapeutics 60 GSK # 60 androgen independent 60 sulindac 60 Catena ® 60 MGCD# [001] 60 erlotinib Tarceva ® 60 novel anticancer 60 pro apoptotic 60 desvenlafaxine succinate 60 Hedgehog pathway 60 B lymphocyte stimulator 60 CIMZIA TM 60 Ophena TM 60 NS5A 60 oral salmon calcitonin 60 Abeta# 60 Drug Candidate 60 lowers blood glucose 60 transgene expression 60 Lp PLA 2 60 anti leukemic 60 myelofibrosis polycythemia vera 60 peptide hormone 60 galectin 3 60 urate oxidase 60 amnestic mild cognitive impairment 60 Synavive 60 splice variants 60 Angiotensin II 60 busulfan 60 selective adenosine 60 Aurora kinase inhibitor 60 selective agonists 60 RLY# 60 5 HT2A inverse 60 LSI #P 60 ghrelin agonist 60 antidiabetic drug 60 oral nucleoside analogue 60 NPD1 60 p# alpha [001] 60 aMCI precursor 60 potent inhibition 60 Valortim ® 60 Tezampanel 60 potency selectivity 60 RBP4 60 intracellular uptake 60 Alzhemed TM 60 Angiocept 60 dopamine D2 60 EGFr 60 antisense inhibition 60 #D#C# 60 Elvitegravir 60 K ras 60 osteocalcin 60 protein tyrosine phosphatase 1B 60 inhibitory effects 60 investigational monoclonal antibody 60 TRAIL R2 60 PDE# 60 LPA1 receptor 60 ALN HPN 60 pleiotropic 60 Tyrosine Kinase Inhibitor 60 Smurf1 60 drug metabolizing enzyme 60 potent cytotoxic 60 IL 1β 60 hedgehog pathway 60 potent antitumor 60 pDCs 60 LHRH antagonists 60 CEACAM1 60 ANAVEX #-# [001] 60 5 HT4 receptor 60 STRIDE PD 60 MYDICAR ® 60 atypical neuroleptics 60 monocyte chemoattractant protein 60 octreotide acetate 60 antifibrotic 60 INGN 60 alkaline phosphatase ALP 60 retinoic acid receptor 60 registrational trial 60 methylated DNA 60 CLORETAZINE TM VNP#M 60 EP #R 60 AtuRNAi 60 Chemokine Receptor 60 Fenretinide 60 norepinephrine reuptake inhibition 60 neovascular 60 ritonavir boosted 60 HDAC 60 cytochrome P 60 edifoligide 60 ORMD 60 enkephalin 60 S#A# [002] 59 HGS ETR1 mapatumumab 59 small molecule inhibitors 59 DNA intercalator 59 E1 INT TM 59 adipogenic 59 Pentraxin 2 59 alpha antagonist 59 Interferon Beta 59 IL #R 59 zanolimumab 59 MMP2 59 VIPR2 59 APOE e4 59 KB# [002] 59 nicotinic acetylcholine receptor 59 MAPK signaling pathway 59 NN# [001] 59 favorable pharmacokinetic 59 Aplidin 59 YONDELIS 59 SERCA2a 59 CRAC channel 59 serotonin norepinephrine reuptake inhibitor 59 evaluating tivozanib 59 eNOS 59 prodrug 59 naturally occurring molecule 59 BNC# 59 anticancer compound 59 myeloproliferative disorders 59 pro angiogenic 59 neuroregenerative 59 glucose transporter 59 PEGPH# 59 enzyme inhibitor 59 transgenic rats 59 TELINTRA 59 cell adhesion molecule 59 erlotinib Tarceva 59 Enzyme Replacement Therapy 59 HCD# [002] 59 Pharmacokinetics PK 59 prolyl 59 MET amplification 59 HDACs 59 Randomized Phase 59 Posiphen TM 59 kinase inhibitor 59 AZD# 59 kallikrein 59 diarrhea predominant irritable 59 activating mutation 59 pharmacokinetic parameters 59 Phase 2b Trial 59 TRAIL R1 59 HepDirect prodrug 59 Tanespimycin 59 adrenergic regulation 59 redox active 59 visilizumab 59 phosphorylated tau 59 Beta catenin pathway 59 IGF IR 59 neurokinin 1 59 GMX# 59 FGFR1 59 Genz # 59 Laquinimod 59 PRX # 59 fibulin 59 Glypromate 59 SGPT 59 amyloid deposition 59 HMG CoA reductase inhibitor 59 AZILECT ® 59 novel peptide 59 glucokinase 59 fatty acid amide hydrolase 59 NR2B 59 dyskinesia PD LID 59 β catenin 59 Inosine 59 forodesine 59 bortezomib Velcade 59 PEGylated anti 59 Nanobody ® 59 β2 59 C1 INH 59 FOXP3 59 IgG1 59 Varespladib 59 agonism 59 GDIR 59 Pathway Inhibitor 59 ULORIC 59 incyclinide 59 CYT# 59 Amigal 59 iroxanadine 59 receptor antagonism 59 TNFalpha 59 eprotirome 59 SAR# [004] 59 TRO# 59 TG# [003] 59 Tumor Necrosis Factor 59 factor G CSF 59 ß2 59 VAPRISOL 59 annexin 59 ADP receptor antagonist 59 endothelial nitric oxide 59 AGHD 59 GW# [003] 59 5 HT4 59 TNF Tumor Necrosis Factor 59 oral bioavailability 59 CYT# QbG# 59 p# MAPK 59 DDP# 59 cytochrome P# enzymes 59 Bafetinib 59 Pgp 59 tubulin inhibitor 59 GLP 1R 59 hepatoma 59 OHR/AVR# 59 SB# ONX 59 IMiDs 59 evaluating satraplatin 59 nNOS 59 Recombinant Human 59 vitro experiments 59 refractory prostate cancer 59 inhaled AAT 59 tanespimycin 59 proteasome inhibitor 59 geldanamycin 59 potently inhibits 59 neuronal nicotinic receptors NNRs 59 Tarceva TM